A biorepository, also known as a biobank or biostorage facility, is a specialized facility that collects, stores, and manages biological samples or specimens, such as tissues, blood, DNA, RNA, cells, and other biological materials, for research and clinical purposes.

Biorepositories play a crucial role in advancing scientific knowledge and medical research, but biopharma companies are often faced with the question of whether it’s best to build an in-house biorepository facility from scratch or work with an outsourced CDMO partner who can provide immediate access to a range of ready-made biorepository solutions.

Among the advantages, working with an established biorepository partner like a CDMO provides access to state-of-the-art facilities and specialized expertise at a lower cost than building a biorepository in-house.

Additionally, it offers industry expertise from seasoned professionals who can ensure samples are handled and stored correctly—whether at a single location or multiple sites to help facilitate research needs in different locations. Some of the challenges associated with outsourcing are the loss of control and customization over the biorepository’s operations and the lack of immediate access to samples.

This article examines the pros of building a biorepository in-house compared to the pros of buying a biorepository through an outsourced partner and outlines the advantages and disadvantages biopharma companies are likely to experience with either option. It’s important to remember there’s no one-size-fits-all approach, and that every research project has its own unique goals to consider.

Download the full article to read more